FindTrial
Sign In

Identification and product development of biomarkers for early diagnosis and risk assessment of senile prostatic hyperplasia

Identification and product development of biomarkers for early diagnosis and risk assessment of senile prostatic hyperplasia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049148
Enrollment
Unknown
Registered
2021-07-23
Start date
2021-07-23
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign prostatic hyperplasia

Interventions

Gold Standard:Clinical outcome
Index test:Total&#32
PSA&#32
kit&#32
(latex&#32
immunoturbidimetry),&#32
free&#32
immunoturbidimetry)&#32
automatic&#32
biochemical&#32
analyzer

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Male; 2. >=40 years old; 3. International Prostate Symptom Scale (IPSS), score >= 8 points.

Exclusion criteria

Exclusion criteria: 1. Poor general condition; 2. Increased serum PSA; 3. Blood disease; 4. There is a tendency to bleeding; 5. Drug addiction (including drug, narcotic and alcohol addiction); 6. Have mental illness and cannot cooperate with rehabilitation treatment.

Design outcomes

Primary

MeasureTime frame
total prostate specific antigen;free prostate specific antigen;acid phosphatase;—

Countries

China

Contacts

Public ContactZhang Chunyan

Chinese PLA General Hospital

rebrcca@126.com+86 18810882866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026